[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"haematological-malignancies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:haematological-malignancies":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100577341","proof-of-concept-to-assess-the-feasibility-of-a-decentralised-pathway-coordinated-by-the-advanced-practice-nurse-for-patients-receiving-oral-treatment-for-cancer-or-malignant-haemopathy-acceler-platform-100577341",false,"NCT06797037","Proof of Concept to Assess the Feasibility of a Decentralised Pathway Coordinated by the Advanced Practice Nurse for Patients Receiving Oral Treatment for Cancer or Malignant Haemopathy (ACCELER PLATFORM)","Inclusion Criteria:\n\n1. Patient over 18.\n2. A patient with solid cancer or haematological malignancy receiving oral retroceded therapy as part of standard management.\n3. Patient with a performance index (ECOG): 0-2.\n4. Patient contactable by telephone for follow-up by the Advanced Practice Nurse.\n5. Patient willing to make two home visits within 6 months of inclusion.\n\nExclusion Criteria:\n\n1. Pregnant or breast-feeding patient.\n2. Any psychological, family, geographical or social condition which, in the judgement of the oncologist, could potentially prevent the collection of informed consent or hinder compliance with the study protocol.\n3. Patients deprived of their liberty by administrative or legal decision, or patients under guardianship.","ALL","18 Years",{"count":18,"type":19},33,"ESTIMATED","INTERVENTIONAL",[22],"NA","This is an open-label, single-centre, category 2 \"Jardé Law\" proof-of-concept study designed to demonstrate the feasibility of a decentralised care pathway for patients with cancer or haematological malignancies receiving oral treatment.\n\nThe study will be conducted on a population of 33 patients.\n\nIn current practice, patients with certain solid cancers or haematological malignancies may be prescribed oral chemotherapy on a retroceded basis. In these cases, the oncologist (coordinating investigator) sees the patient for a consultation every 3 cycles to prescribe\u002Frenew the treatment for approximately 3 months. Every month, the patient returns to the centre to have the treatment dispensed by the hospital pharmacy. No medical consultation is associated with this visit.\n\nIn this study, it is proposed to decentralise the delivery of treatment to these patients by introducing two visits to the patient's home by a service-providing nurse.\n\nThe decentralised patient pathway will be organised and monitored by the Advanced Practice Nurse (APN) at the investigating centre, who will be responsible in particular for coordination with the service-providing nurse and the hospital pharmacy.",[25,26],"Solid Cancer","Haematological Malignancies",[28],"Retroceded oral chemotherapy","RECRUITING","2026-06-12",{"date":32,"type":33},"2026-06-16","ACTUAL",{"date":35,"type":33},"2025-05-19",{"date":37,"type":19},"2027-05-19",{"name":39,"class":40},"Institut Claudius Regaud","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":41},"100577961","clinical-efficacy-of-platelet-transfusion-100577961","NCT06805097","Clinical Efficacy of Platelet Transfusion","ECLAT","Inclusion Criteria:\n\n* Patients with haematological malignancies or bone marrow aplasia with severe thrombocytopenia due to bone marrow failure related to the disease or treatments received\n* Severe thrombocytopenia requiring transfusion\n* Patient able to self-assess bleeding events\n* Non-opposition of the subject to participate in the study\n* Registered with the French social security system or benefiting from such a system.\n\nExclusion Criteria:\n\n* Acute promyelocytic leukaemia\n* Curative dosage of anticoagulants\n* Treatment with antiplatelet agents\n* Patient with proven thrombocytopenia of immunological origin, or disseminated intravascular coagulation\n* Patients with a clinically significant haemorrhagic event (WHO grade 2) in the 48 hours prior to transfusion\n* Indication for deplasmatised, cryopreserved and reduced-volume PCs\n* Patient refusing transfusion of labile blood products\n* Pregnant women or breast-feeding mothers\n* Adults subject to a legal protection measure or unable to express their consent\n* Persons deprived of their liberty by a judicial or administrative decision; persons under compulsory psychiatric care; persons admitted to a health or social care institution for purposes other than research\n* Subject in the exclusion period of another study",{"count":50,"type":19},343,"OBSERVATIONAL","The aim of this study is to analyze the effect of the storage time of platelet concentrates on the occurrence of bleeding events during prophylactic platelet transfusions in patients with hematological malignancies.",[54,26],"Thrombocytopaenia",[56,57,58],"platelet concentrate","transfusion","haemorrhage","2025-07-04",{"date":61,"type":33},"2025-07-09",{"date":63,"type":33},"2025-06-17",{"date":65,"type":19},"2028-07",{"name":67,"class":40},"Centre Hospitalier Universitaire de Besancon",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":75,"minAge":16,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":20,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":41},"100579850","cryopreserved-ovarian-tissue-transplantation-in-patients-who-have-survived-sarcomas-and-hematological-tumors-100579850","NCT06829654","Cryopreserved Ovarian Tissue Transplantation in Patients Who Have Survived Sarcomas and Hematological Tumors","Safety Assessment Of Cryopreserved Ovarian Tissue Transplantation In Patients Who Have Survived Sarcomas And Hematological Tumors","Inclusion Criteria:\n\nFor all groups:\n\n* Patients with Ewing (ES) and synovial (SS) sarcoma, acute lymphoblastic leukemia (LLA), acute myeloid leukemia (LMA), chronic myeloid leukemia (LMC) and myelodysplasia (MDS)\n* No objection to the procedure of sampling for cryopreservation or reimplantation of ovarian tissue by the patient's reference oncologist (according to PA105)\n* Obtaining informed consent.\n\nGroup 1:\n\n* Age \\>18 and under 38 at the time of cryopreservation\n* Request for cryopreservation of ovarian tissue at the Laboratory Cryopreservation Ovarian Tissue and Cell Cultures\u002FCriobank IRCCS AOUBO\n\nGroup 2:\n\n* Age \\>18 years\n* Ovarian tissue already collected and cryopreserved at the Laboratory for Cryopreservation of Ovarian Tissue and Cell Cultures\u002FCriobank IRCCS AOUBO\n\nGroup 3\n\n* Age \\> 18 years\n* Request for reimplantation of cryopreserved ovarian tissue at the Laboratory for Cryopreservation of Ovarian Tissue and Cell Cultures\u002FCriobank IRCCS AOUBO\n* Early menopause or menstrual irregularities\n\nExclusion Criteria:\n\nGroup 1 and 3\n\n* Contraindications to laparoscopy\n* HIV, hepatitis B and C, treponema pallidum and positive PAP tests\n* Malignant disease involving the ovary or samples to be reimplanted\n\nGroup 2 None.","FEMALE","38 Years",{"count":78,"type":19},80,[22],"The study aims to test for the presence or absence of primary tumor-specific tumor markers in ovarian tissue. Therefore, there will be a first phase in which pathology-specific markers will be identified in the patients' diagnostic pathological material by histological, immunohistochemical, and molecular analysis; then, tumor markers will be sought in cryopreserved ovarian tissue.",[82,26],"Sarcomas",[84,85,86,87],"sarcomas","haematological malignancies","cryopreservation","ovarian tissue","2025-02-11",{"date":90,"type":33},"2025-02-17",{"date":92,"type":33},"2024-08-12",{"date":94,"type":19},"2026-08-12",{"name":96,"class":40},"IRCCS Azienda Ospedaliero-Universitaria di Bologna"]